Establishment Labs Shares Promising Mia Femtech Results at Symposium
Establishment Labs' Groundbreaking Mia Femtech Findings
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on enhancing women’s health, has showcased impressive three-year clinical results utilizing their innovative Mia Femtech™ technology. This presentation took place at a notable global event, the 9th Annual World Symposium on Ergonomic Implants. The symposium aims to gather top professionals in the plastic surgery field to exchange advancements in practices and technology, and it is being held in Barcelona.
Mia Femtech Clinical Study Overview
The Mia Femtech Clinical Study is a thoroughly vetted, IRB-approved prospective study. It enrolled a total of 100 participants between late 2020 and the early months of 2021, analyzing significant complications. In a preliminary review of the study, strikingly, there were no instances of capsular contracture nor observed ruptures. The findings indicate no reports of infections, hematomas, or seromas that required medical intervention, and participants did not experience changes to nipple or breast sensation. An exemplary follow-up compliance rate of 93% was noted for the three-year analysis.
Highlights From the Symposium Presentation
The World Symposium on Ergonomic Implants fosters connections among over 500 plastic surgeons, researchers, and commercial partners from around the world. During this event, they dive into scientific discussions concerning advancements like breast tissue preservation technologies. Juan José Chacón-Quirós, the founder and CEO of Establishment Labs, presented the valuable outcomes of the Mia study, underscoring its place as one of the most promising breast implant data sets reported over three years. According to him, these results affirm a shift towards minimally invasive solutions in breast aesthetics.
Demand Surge and Future Prospects
The reception of Mia in current markets has been overwhelmingly positive. Surgeons and clinic partners that adopted this technology over the past year have contributed to increased demand, which now appears to be reaching a pivotal point. Chacón-Quirós emphasized the recent FDA approval of Motiva implants as a significant milestone, signaling their ambitions to introduce this cutting-edge technology to the United States market.
Clinical Data Insights
In the context of the clinical findings, the study provided the following data on key complications:
- Capsular contracture (Baker Grade III/IV): 0.0%
- Ruptures (suspected or confirmed): 0.0%
- Infections: 0.0%
- Seromas: 0.0%
- Hematomas: 0.0%
- Changes in nipple sensation: 0.0%
- Changes in breast sensation: 0.0%
- Malposition/Displacement: 1.0%
- Any reoperation: 1.0%
It’s important to note that this data is preliminary and does not fully represent the complete results or the overall efficacy and safety of the Mia Femtech procedure.
About Establishment Labs
Establishment Labs Holdings Inc. is at the forefront of medical technology, dedicated to improving health and wellness among women through innovative science and engineering. The company’s expansive portfolio of Femtech solutions focuses on breast health, aesthetics, and reconstruction. Since its inception, nearly four million Motiva devices have been delivered to plastic and reconstructive surgeons across over 85 countries, establishing a new benchmark for safety and satisfaction. Among its several products, the Motiva Flora tissue expander is renowned for its effectiveness in breast reconstruction post-cancer, being the only expander globally approved with an integrated port that utilizes radio-frequency technology and is MRI conditional.
The Mia Femtech experience, which offers a unique minimally invasive approach to achieving breast harmony, stands as the latest innovative stride from Establishment Labs. The company supports its solutions with a robust portfolio of patent applications worldwide and over 100 clinical studies published in peer-reviewed journals. Manufacturing takes place in two compliant facilities in Costa Rica which meet rigorous regulatory standards.
Frequently Asked Questions
What is Mia Femtech technology?
Mia Femtech is an innovative, minimally invasive procedure developed by Establishment Labs for improved breast aesthetics and reconstruction.
What were the key outcomes from the Mia Femtech clinical study?
The study highlighted a 0.0% rate for significant complications such as capsular contracture and ruptures, indicating a promising safety profile.
How many subjects participated in the clinical study?
A total of 100 subjects were enrolled in the Mia Femtech clinical study, providing robust and insightful data.
When and where was the World Symposium on Ergonomic Implants held?
The symposium took place in Barcelona, presenting new scientific data from experts in the field focusing on advancements in breast surgery.
How does Establishment Labs support women's health?
Through innovative technology and research, Establishment Labs provides solutions aimed at enhancing women's breast health, aesthetics, and overall wellness.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Recent Articles
- BlueWind Medical Presents iTNM as Promising UUI Solution
- Scholar Rock Unveils Key Data from the DRAGON Trial at SITC Meeting
- OWC Unveils Thunderbolt 5 Solutions for Next-Gen Macs
- Trisura Group Prepares for Q3 2024 Financial Results Release
- Rä Foods Expands Wild About Sprouts® Across Whole Foods Markets
- Martin Marietta's Debt Offering Promises Strong Investor Appeal
- CrowdStrike Excels in Gartner's 2024 Endpoint Protection Evaluation
- Celebrating Tax Deferral: IPX1031's Engaging 10-31 Video
- Innovative AI and Robotics Enhance ITAD Services in California
- Verastem Oncology Advances Innovative Treatment for Ovarian Cancer
- Intouch Insight Appoints Sarah Beckett as VP of Sales and Marketing
- Cohu Innovates with New SiC Burn-In Testing Equipment
- Richards Packaging Reports Q3 Results Amidst Market Challenges
- Empowering Oncology: KORU Medical Systems Enhances Drug Delivery
- Cohu's Innovative Neon Platform Revolutionizes HBM Market
- Bectran's Innovative Solutions Shine in Construction Tech Awards
- Phibro Animal Health's Major Acquisition Enhances Product Portfolio
- Open Banking Market Expected to Surge with AI Innovations
- Explore Luxury Living: First Condominiums at The Emory
- S&W Seed Company Announces Fiscal Year 2024 Financial Highlights
